KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Finished Goods: 2010-2021

Historic Finished Goods for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Sep 2021 value amounting to $261.6 million.

  • Biomarin Pharmaceutical's Finished Goods fell 20.79% to $261.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $261.6 million, marking a year-over-year decrease of 20.79%. This contributed to the annual value of $313.6 million for FY2020, which is 22.57% up from last year.
  • As of Q3 2021, Biomarin Pharmaceutical's Finished Goods stood at $261.6 million, which was up 3.29% from $253.3 million recorded in Q2 2021.
  • Biomarin Pharmaceutical's 5-year Finished Goods high stood at $330.3 million for Q3 2020, and its period low was $129.6 million during Q2 2017.
  • Over the past 3 years, Biomarin Pharmaceutical's median Finished Goods value was $255.9 million (recorded in 2019), while the average stood at $259.8 million.
  • Its Finished Goods has fluctuated over the past 5 years, first spiked by 70.09% in 2018, then fell by 20.79% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Finished Goods (Quarterly) stood at $191.2 million in 2017, then increased by 17.76% to $225.2 million in 2018, then rose by 13.62% to $255.9 million in 2019, then increased by 22.57% to $313.6 million in 2020, then dropped by 20.79% to $261.6 million in 2021.
  • Its Finished Goods stands at $261.6 million for Q3 2021, versus $253.3 million for Q2 2021 and $279.6 million for Q1 2021.